Olema Pharmaceuticals (OLMA) Operating Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Operating Expenses data on file, last reported at $58.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 66.28% year-over-year to $58.0 million in Q1 2026; TTM through Mar 2026 was $201.8 million, a 41.33% increase from a year earlier, with the FY2025 full-year figure at $178.7 million, up 25.62% from the prior year.
• Operating Expenses for Q1 2026 stood at $58.0 million, up from $50.1 million in the prior quarter.
• Over the last five years, Operating Expenses for OLMA reached as high as $58.0 million in Q1 2026 and fell as low as $21.6 million in Q2 2023.
• Historically, Operating Expenses has averaged $34.8 million across 5 years, with a median of $33.5 million in 2024.
• Across the five-year window, Operating Expenses soared 101.51% in 2022 and sank 35.12% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $27.2 million in 2022, then increased by 11.75% to $30.4 million in 2023, then grew by 20.88% to $36.8 million in 2024, then surged by 36.22% to $50.1 million in 2025, then rose by 15.78% to $58.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $58.0 million in Q1 2026, $50.1 million in Q4 2025, and $45.9 million in Q3 2025.